Simply Sleep

New OTC sleep aid "from the makers of Tylenol PM" contains 25 mg diphenhydramine per caplet, the same ingredient and dosage level as in Tylenol PM but without the 500 mg acetaminophen. TV ads for the product say: "While some folks couldn't sleep...", showing a restless man in a bathrobe in front of a TV, presumably in the wee hours of the morning. The shot then shifts to the house next door where a woman is sleeping comfortably. The ad continues:"...you were peacefully sleeping, thanks to new Simply Sleep from the makers of Tylenol PM. It's non-habit forming and eases you into a restful night's sleep. New Simply Sleep." The ad includes a product shot of Simply Sleep's night blue box with a half moon design and corner banner "New." The phrase "from the makers of Tylenol PM" is similar in context to that used by the Clear Passage nasal strips from the makers of Afrin (Schering-Plough) ("The Tan Sheet" July 20, 1998, p. 2). McNeil Consumer Healthcare began shipping Simply Sleep in February. The sleep aid comes in two SKUs, a 24-count for $3.99-$4.29 suggested retail price and a 48-count for $6.19-$6.99

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

US FDA Could Seek Stronger Warnings On SSRI Antidepressant Risks During Pregnancy

 
• By 

Testimony during a July 21 ‘expert panel’ could help justify stronger warnings across the class about potential adverse effects on mother and baby. Panelists ranged from clinicians who said depression during pregnancy should be treated, to those who said sadness has been “medicalized."

World’s First Hemato-Oncology Microbiota Therapeutic Among Latest New EU Filings

 

The European Medicines Agency has started reviewing for potential EU marketing approval six new products, including MaaT Pharma’s microbiota therapeutic for acute-graft-versus-host disease, and AstraZeneca's camizestrant for locally advanced or metastatic breast cancer.

Sponsors Asked, EMA Delivered: One Handbook To Navigate CTIS

 
• By 

The European Medicines Agency has revised the sponsor handbook for the Clinical Trials Information System, bringing together guidance that was previously scattered across multiple platforms and documents to help sponsors navigate the trial process more efficiently.